Scarica l'app Stockscreener
0.377
5.70%
-0.0228
Dopo l'orario di chiusura:
.38
0.003
+0.80%
Precedente Chiudi:
$0.3998
Aprire:
$0.3953
Volume 24 ore:
660.17K
Relative Volume:
1.09
Capitalizzazione di mercato:
$22.02M
Reddito:
-
Utile/perdita netta:
$-123.46M
Rapporto P/E:
-0.1456
EPS:
-2.59
Flusso di cassa netto:
$-104.11M
1 W Prestazione:
+1.73%
1M Prestazione:
-4.56%
6M Prestazione:
-24.54%
1 anno Prestazione:
-77.95%
Intervallo 1D:
$0.3718
$0.415
Intervallo di 1 settimana:
$0.3254
$0.415
Portata 52W:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Nome
Bioatla Inc
Settore
Industria
Telefono
858-558-0708
Indirizzo
11085 TORREYANA ROAD, SAN DIEGO
Confronta BCAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.377 | 19.94M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-05-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-06-28 | Iniziato | ROTH Capital | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | BTIG Research | Buy |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | JP Morgan | Overweight |
| 2021-01-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Bioatla Inc Borsa (BCAB) Ultime notizie
What analysts say about BioAtla Inc. stockConsistently high returns - Autocar Professional
What drives BioAtla Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com
BioAtla Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com
Is Now The Time To Buy BioAtla Inc (NASDAQ: BCAB) Stock? - Stocksregister
Is BioAtla Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Is BioAtla Inc. stock a good hedge against inflationFree Consultation - Newser
What analysts say about BioAtla Inc. stock outlookFast Gains With Reduced Risk - beatles.ru
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - The Manila Times
What makes BioAtla Inc. stock price move sharplyTrending Stock Alert - Newser
Why BioAtla Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
How BioAtla Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
BioAtla (NASDAQ:BCAB) Stock Price Up 2.6% – Here’s Why - Defense World
BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma - Yahoo Finance
BioAtla Approves 2025 Corporate Bonus Plan - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World
Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World
Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times
BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan
BioAtla’s SWOT analysis: CAB platform stock faces pivotal year amid clinical trials - Investing.com Nigeria
Bioatla Inc Azioni (BCAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):